REVIEW article
Front. Immunol.
Sec. Cytokines and Soluble Mediators in Immunity
This article is part of the Research TopicRegulation of Cytokine and Growth Factor Signaling in Health and DiseaseView all articles
The role of interleukin-37 and interleukin-38 in the development and remission of autism spectrum disorder: A comprehensive review of neuroinflammatory mechanisms and potential therapeutic implications
Provisionally accepted
- 1United Arab Emirates University College of Medicine and Health Sciences, Al Ain, United Arab Emirates
- 2United Arab Emirates University, College of Science, Al Ain, United Arab Emirates
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Autism spectrum disorder (ASD) is a complicated neurodevelopmental syndrome characterized by abnormalities in social communication, lack of interests, and repetitive behaviors. Increasing evidence from recent studies indicates that neuroinflammation and immunological dysregulation play essential roles in the pathogenesis of ASD. This review consolidates current knowledge on two anti-inflammatory cytokines of the IL-1 family, interleukin-38 (IL-38) and interleukin-37 (IL-37), which have recently emerged as essential modulators of neuroimmune mechanisms in ASD, highlighting their emerging roles in ASD pathogenesis and therapeutic potential. Based on a combination of clinical and experimental findings, IL-38 has been reported to exert anti-inflammatory effects by suppressing microglial activation and reducing the release of pro-inflammatory cytokines. Consequently, modulation of IL-38/IL-36R signaling axis appears to represent a crucial mechanism regulating neuroinflammation in brain regions relevant to autism. On the other hand, studies indicate that IL-37 exhibits a consistent upregulation in the brain tissues associated with ASD, functioning via IL-37/IL-18Rα/IL-1R8 pathway, where it inhibits cytokine synthesis, alters microglial polarization, and affects communication along the gut–brain axis. While these findings establish IL-38 and IL-37 as possible biomarkers for ASD diagnosis and treatment targets, these investigations are still emerging. This review establishes the foundation for understanding the growing importance of cytokines and highlights the requirement for further research to clarify their roles and to formulate potential treatment approaches for ASD.
Keywords: Interleukin-37, Interleukin-38, Autism Spectrum Disorder, Neuroinflammation, Microglia, Cytokines, therapeutic targets
Received: 30 Sep 2025; Accepted: 17 Nov 2025.
Copyright: © 2025 Al Rasbi, Orsud, Zoughbor, Hajar, Mahboob and SADEK. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: BASSEM SHABAN SADEK, bassem.sadek@uaeu.ac.ae
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.